PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33829606-3	2021	The objective of the present study was to assess the relationship between the XPC Ala499Val (rs2228000 C>T) and Lys939Gln (rs2228001 A>C) non-synonymous polymorphisms and susceptibility to CML pathogenesis, disease progression, and response to targeted therapeutic regimen, Imatinib Mesylate.	Imatinib Mesylate	274-282	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	78-81	
20575039-0	2010	XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.	Imatinib Mesylate	57-65	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	0-3	
20575039-5	2010	ERCC5 and XPC SNPs correlated with the response to imatinib.	Imatinib Mesylate	51-59	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	10-13	
20575039-6	2010	Haplotype analysis of XPC showed that the wild-type haplotype (499C-939A) was associated with a better response to imatinib.	Imatinib Mesylate	115-123	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	22-25